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Background: Graves’ disease is an independent risk factor for transient postoperative hypoparathyroidism. Besides
the disease itself, preparation techniques are influential. Transient postoperative hypoparathyroidism has severe
consequences for patients’ physical and psychological state. It can be life threatening during the acute phase and
may impair patients’ health, psyche and quality of life thereafter. For the surgical therapy of Graves’ disease, total
thyroidectomy is recommended according to the national S2-guideline. The evidence- based on a metaanalysis- is
criticized by the Cochrane diagnostic review commentary for substantial methodological deficits. Two randomized
controlled trials lead to the hypothesis that a near-total resection with bilateral remnants of ≤ 1g on each side
compared to total thyroidectomy will significantly reduce the occurrence of transient postoperative
hypoparathyroidism with equal therapeutic safety.
Methods/Design: Patients with Graves’ disease indicated for definite surgery are eligible for the trial. Trial-specific
exclusion criteria are: conservative treatment, malignancy, previous thyroid surgery and coincident
hypoparathyroidism. The trial is created for therapeutic purpose through process innovation. It is designed as a
prospective randomized controlled patient and observer blinded multicentered trial in a parallel design including
an active comparator and an intervention group. The intervention addresses the surgical procedure: near-total
thyroidectomy leaving bilateral remnants of ≤ 1g on each side in the intervention group and total thyroidectomy
in the control group. The occurrence of transient postoperative hypoparathyroidism is defined as primary endpoint.
Secondary endpoints are: reoperations due to bleeding, recurrent laryngeal nerve palsy, permanent
hypoparathyroidism, recurrent disease, changes of endocrine orbitopathy and quality of life within a one-year
follow-up period. The primary efficacy analysis follows the intention-to-treat principle. A binary logistic regression
model will be applied. Complications and serious adverse events will be descriptively analyzed.
Discussion: The trail is expected to balance out the shortcomings of the current evidence. It will define the surgical
gold standard for the surgical therapy of Graves’ disease. Patients’ safety and quality of life are assumed to be
enhanced. Therapy costs are likely to be reduced and health care optimized. The conduction of the trial is feasible
through the engagement and commitment of the German association of endocrine surgeons and the National
Network for Surgical Trials.
Trial registration: German clinical trials register (DRKS) DRKS00004161
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Graves’ disease has been identified as an independent
risk factor for transient postoperative hypoparathyroi-
dism in retrospective trials. It was confirmed by a compre-
hensive prospective study including 5,846 consecutive
patients in 2003 [1]. In the only existing randomized
controlled trial, transient hypoparathyroidism is reported
with an incidence of 28% after total thyroidectomy for
Graves’ disease [2]. The estimated prevalence is calcu-
lated with 2,000 patients per year according to the
available data [2-4]. The underlying causes are com-
plex. Preparation techniques, especially the extent of
resection seem to be more influential than inadvertent
parathyroidectomy [1,5]. Postoperative hypoparathyr-
oidism seriously affects physical health, wellbeing and
quality of life. Acute hypocalcaemia can cause cram-
ping, bronchial spasms, cardiac and digestive dysfunc-
tion and can therefore be life threatening. Long-term
effects result in cataract, conjunctivitis, pruritus, osteo-
penia, calcifications of the basal ganglia (Fahr’s syn-
drome), neurological and psychic impairments. Despite
calcium and vitamin D substitution, wellbeing is pre-
dominantly impaired by anxious and phobic psycho-
logical disorders [6]. Care and treatment costs as well as
the status of employee’s illness are therefore of eco-
nomic relevance.
At present, total thyroidectomy is favored for definite
surgery in Graves’ disease instead of subtotal resection,
according to the national S2-guideline issued by the Work
Group of the Scientific Medical Professional Societies
(AWMF) [7]. The current evidence supporting a total
thyroidectomy in Graves’ disease is based on two rando-
mized controlled trials [2,8], one meta-analysis [9] and
four retrospective trials [10-13]. All studies evaluate the
outcome after total versus subtotal thyroidectomy, in re-
lation to the incidence of recurrent disease. The meta-
analysis, cited in the national S2-guideline, displayed a
zero-recurrence rate and an equal risk of method-asso-
ciated complications [9]. However, the corresponding Co-
chrane diagnostic review commentary emphasizes group
inhomogeneity as a substantial methodological deficit.
Four retrospective trials [10-13] demonstrated a signifi-
cantly lower incidence of transient hypoparathyroidism
after subtotal, compared to total resections, while the inci-
dence of recurrent disease differed according to variable
sizes of the remnants (mean 6.1 g, range 1 to 12 g) and
follow-up periods. Among these four trials only one
clearly defined the size of the remnant with a unilateral re-
sidual thyroid tissue of ≤ 2 g when a subtotal resection
was performed [13]. With this measure, the incidence of
hypoparathyroidism significantly decreased, while the inci-
dence of recurrent disease remained unaltered within a
median follow-up of 6.7 years. The recurrence rate of
0.5% in this study was attributable to inadvertently sparedpyramidal lobes in all patients as the result of a systematic
default. Two prospective randomized controlled trials by
Witte et al., 2000 [2] and Barczynski et al., 2012 [8] again
aimed at recurrence of Graves’ disease as the primary end-
point, addressing different remaining tissue volumes and
resection techniques. The trial by Witte et al. compared
two interventional arms: one arm comprised a unilateral
total resection and a contralateral subtotal resection with
a remaining remnant of ≤ 4 g; the second arm comprised
a bilateral subtotal resection with a remaining remnant
of ≤ 4 g in total to the control arm total thyroidectomy.
Barczynski et al. considered bilateral remnants of approxi-
mately 2 g on each side. Both trials displayed a signifi-
cantly lower incidence of transient hypoparathyroidism in
the intervention groups. While the incidence of recurrent
disease was not significant, clinically not relevant, and de-
tectable in all affected patients six months after surgery,
after a follow up of 18 to 58 months in the trial by Witte
et al., Barczynski et al. reported significantly higher re-
lapse rates within 60 months follow up. Endocrine orbito-
pathy did not worsen after subtotal resection in both
trials. So far, the evidence from the prospective rando-
mized controlled trials seems contradictory regarding the
incidence of clinically relevant recurrent disease. More-
over, the S2-recommendation lacks appropriate evidence
in view of comorbidities. According to our knowledge, the
incidence of transient hypoparathyroidism has never been
valued as primary endpoint. Current data suggest a rele-
vant reduction of the incidence of transient hypoparathyr-
oidism after a near-total resection if defined remnants of
≤ 1 g on each side are left around the posterior suspensory
ligament of Berry (Ligamentum thryoihyoideum laterale).
The resection will be safe compared to standard total thyr-
oidectomy regarding recurrent disease, endocrine orbito-
pathy and method associated complications [2,9,13]. A
prospective randomized controlled trial is necessary to de-
fine the gold standard resection for the surgical therapy of




Patients with Graves’ disease scheduled for definite sur-
gery are eligible for the present study. Indications for
definite surgery follow those of the national S2-guideline
[7], in detail a high risk of recurrence (age below 40
years, male gender, thyroidea receptor anti-body (TRAK)
serum levels > 10 U/l six months after conservative
treatment, thyroid volume > 40 ml), persistent, recurrent
or severe hyperthyroidism after primarily conservative
therapy, thyroid growth, endocrine orbitopathy and
refused radioactive iodine therapy. After a screening visit
patients will be allocated into the trial according to the
inclusion and exclusion criteria shown below.
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Key inclusion criteria are: indication for definite surgery
according to the national guideline, no history of previ-
ous thyroid and/or parathyroid surgery, normal vocal
cord function, age greater than 18 years, expectancy of
life greater than 12 months, and provision of informed
consent.
Exclusion criteria
Exclusion criteria are: eligibility for conservative treat-
ment according to the national guideline, (suspected)
malignancy, coincident hyperparathyroidism, and neuro-
physiological deficiencies.
Intervention and control
The study is designed as a prospective, randomized, con-
trolled, observer- and patient-blinded, multicentered
clinical trial in a parallel design, including an interven-
tion group and an active comparator. The intervention
addresses the surgical procedure. It is defined as near-
total thyroidectomy with bilateral remnants ≤ 1 g on
each side for inclusion in the intervention group. After
ligation of the upper pole vessels, and identification and
preservation of the recurrent laryngeal nerve and para-
thyroid glands, the thyroid is removed from the lateral
tracheal wall up to the superior suspensory ligament of
Berry (ligamentum thyreohyoideum laterale). Here, the
thyroid is resected leaving a piece of tissue assessed by
ruler measurement accounting for 0.5 × 0.5 × 0.5 cm in
size at most (≤ 1 g). After resection, the remnant in situ
is photo documented. To ensure adequate sizes of the
thyroid remnants in the intervention group, after re-
moval of the specimen a representative piece of thyroid
tissue (≤ 1 g) is excised, photo documented on a clean
towel next to the ruler and weighed. This tissue frag-
ment is later added to the specimen and both are sent
for histopathology. Surgery in the control group com-
prises a total thyroidectomy where the whole thyroid
gland must be removed [7]. The surgical sites of each
side will be photo documented after resection.
Surgical methods
Cervical approach, preparation, resection approach and
vessel control are not limited per protocol in either
group. The only binding preparation principles in either
group are visualization, monitoring and protection of
the recurrent laryngeal nerve, as well as the identifica-
tion and protection of the parathyroid glands following
the national guideline [7]. Neuromonitoring is per-
formed and recorded before and after resection via the
vagus nerve. If unforeseen multinodular changes, sus-
pected malignancy, or frozen-section assured malig-
nancy requires total thyroidectomy in the intervention
group, or even additional lymphadenectomy in eithergroup, the reason will be documented on the case report
form. Required by the intention-to-treat principle,
patients must be followed up in the group to which they
are randomized.
Definition of endpoints and outcome measures
Primary endpoint
The incidence of transient hypoparathyroidism is
defined as the primary endpoint. Transient hypopara-
thyroidism is defined as an inadequate parathyroid func-
tion not exceeding six months after surgery [14]. Serum
calcium (Ca) and parathyroid hormone (PTH) levels and
substitution medication to achieve normocalcaemia are
used to assess hypoparathyroidism. According to the
best of our knowledge, there is no evidence- or
consensus-based definition of postoperative hypopara-
thyroidism based on calcium and PTH cutoff levels. In
line with most experts, we define postoperative hypo-
parathyroidism as calcium and PTH levels below the
normal range (Ca ≤ 2.1 mmol/l, PTH < 11 ng/l). Post-
operative hypoparathyroidism is considered to be symp-
tomatic in the case of at least one of the following
symptoms: carpo-pedal paresthesia, numbness or
spasms, and anxiety. Application type, form and dosage
of Ca and vitamin D substitution therapy to achieve nor-
mocalcaemia (Ca = 2.2 to 2.7 mmol/l) are registered.
Postoperative hypoparathyroidism is defined transient if
calcium and vitamin-D substitution therapy to achieve
normocalcaemia are required for less than six months
after surgery. The parameters are recorded before sur-
gery, at the day of discharge, 6 weeks, 6 months and 12
months after surgery.
Secondary endpoints
Secondary endpoints comprise the incidences of per-
manent hypoparathyroidism, recurrent Graves’ disease,
temporary and permanent recurrent laryngeal nerve
palsy and reoperations due to bleeding, and the number
of inadvertently removed parathyroid glands, as well as
changes of endocrine orbitopathies and quality of life.
Permanent hypoparythroidism is defined as persisting
inadequate parathyroid function exceeding six months
after surgery [15,16]. The incidence of recurrent Graves’
disease is assessed through laboratory thyroid function
tests as thyroid stimulating hormone (TSH) < 0.34 U/l,
free triiodinethyronine (fT3) > 6.5 pmol/l, thyroxine
(fT4) > 21 pmol/l, and TRAK > 1.75 U/l, at 6 weeks, 6
months and 12 months after surgery, with respect to
concomitant substitution or thyrostatic medications to
achieve euthyrosis, determined by laboratory thyroid
function tests (TSH, fT3, fT4). Cervical ultrasound fol-
lows detection of elevated antibody levels to screen for
recurrence. Reoperations are reported as serious adverse
events. Incidences of temporary and permanent
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laryngoscopy on the day of discharge and in the case of
pathological findings 6 weeks, 6 months and 12 months
after surgery. The number of inadvertently removed
parathyroid glands will be counted from histopathology
reports at the day of discharge. Changes in endocrine
orbitopathy are measured using the validated clinical
eyelid, exophthalmos eye muscle, optic nerve (LEMO)
score [17] before and 12 months after surgery. Changes
in quality of life are scored before surgery and 6 weeks
thereafter using the validated multipurpose question-
naire, the clinical studies 36-item medical outcomes
study short-form general health survey (SF36) [18].Randomization, allocation concealment and blinding
A central randomization will be performed, stratified by
the performing surgeons. Only surgeons who have per-
formed at least 100 thyroidectomies working at a volume
center accounting for more than 100 thyroidectomies
per year will participate. A random sequence will be
generated through computerized random assignment
and concealed allocation. Patients and the observer are
blinded to the applied surgical intervention. Intraopera-
tive randomization will be performed. The surgeon will
be unblinded after the skin incision, and the patient and
the observer will be blinded throughout the whole study
period. All assessments will be performed by personnel
who are blinded to the study arms for the minimization
of measurement bias. Data storage and analyses will be
performed externally.Sample size
The trial is designed on the basis of a critical appraisal
of current evidence. According to the only existing ran-
domized controlled trial by Witte et al. [1], a significant
reduction in the incidence of transient hypoparathyroid-
ism from 28% in the total thyroidectomy group to 12%
in the near-total thyroidectomy group is suspected.
Using a level of significance of 5% and a power of 80%,
97 patients per group are needed to detect the pre-
specific difference when applying a chi square test (2-
sided) without Yates's correction for continuity. With a
dropout rate of 5% between obtaining informed consent
and randomization, a total sample of 206 patients need
to be recruited to the trial. Analysis of the primary end-
point will be performed by an adjusted logistic regres-
sion model. Therefore, it is to be expected that including
covariates of prognostic importance in the logistic re-
gression model will increase the power as compared to
the chi square test. However, since the impact of the
covariates cannot be determined a priori, a potentially
liberal sample size estimation for the chi square test
seems appropriate.Analysis
The primary hypothesis is whether the rate of transient
hypoparathyroidism within 6 months after surgery is
lower in patients after near-total compared to total thyr-
oidectomy. A binary logistic regression model will be
applied for the intervention comparison of the rates,
adjusting for age, gender, hyperthyrosis and endocrine
orbitopathy as additive covariates. The dropout rate can
be assumed to be small, and therefore, few missing
values are expected with respect to the primary end-
point. If missing values occur their reason of omission
will be explored. Depending on the properties and mag-
nitude of missing values, an appropriate estimation will
be specified before the analysis of the primary endpoint.
Concerning other secondary endpoints, exploratory data
analysis will be performed calculating appropriate sum-
mary measures for the empirical distribution as well as
calculation of descriptive two-sided 95% confidence
intervals and P-values. Sensitivity analyses will be con-
ducted for the per-protocol population as well as for
appropriate subgroups. The safety analysis includes cal-
culation and comparison of frequencies and rates of
adverse and serious adverse events. Furthermore, statis-
tical methods are used to assess the quality of data and
the homogeneity of intervention groups.
Discussion
The S2-recommendation of total thyroidectomy for
Graves’ disease based on the national guideline lacks
appropriate evidence in view of morbidity. Total thyroi-
dectomy compared to subtotal or near-total resection
predisposes patients to a relevantly higher risk for transi-
ent postoperative hypoparathyroidism. The consequen-
ces of transient postoperative hypoparathyroidism can
be severe and life threatening during the acute phase
and may impair patient’s psychological state and quality
of life thereafter. According to the existing evidence,
near-total thyroidectomy leaving bilateral remnants
of < 1g on each side is assumed to relevantly reduce the
incidence of transient postoperative hypoparathyroidism
with equal therapeutic safety in terms of recurrent dis-
ease, deterioration of endocrine orbitopathy and
method-associated complications. The trial is likely to
optimize the surgical therapy of Graves’ disease. If a
lower incidence of transient postoperative hypoparathyr-
oidism is assumed, patient’s safety and quality of life are
likely to be enhanced and postoperative care and treat-
ment will be simplified. Care and treatment costs are
likely to be relevantly reduced.
Trial status
The trial manuscript has been reviewed by the Study
Center of the German Surgical Society (SDGC). It has
been approved by the National Network for Surgical
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Visceral Surgery (DGAV). The project was approved by
the German Society of Endocrine Surgery (CAEK) at
their 30th annual meeting on the 26th of November
2011 in Innsbruck, Austria. So far 20 high volume cen-
ters assigned a preliminary declaration of commitment
with a mean number of 23 estimated patients to be
enrolled within 12 months. The local ethics committee
of the Philipps-University of Marburg approved the trial
giving a positive vote on the 25th of April 2012 (leading
ethics committee number 35/12). The trial is registered
at the German Clinical Trials Register (DRKS) (trial
number DRKS 00004161). Financing is applied within
the governmental funding program for clinical trials of
the German Ministry for Education and Research
(BMBF). The Study team is awaiting BMBF response.
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